What is the recommended dosage of Ranolazine for chronic angina?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 22, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Recommended Dosage of Ranolazine for Chronic Angina

The recommended dosage of ranolazine for chronic angina is to start with 500 mg orally twice daily, which can be increased to a maximum of 1000 mg twice daily based on clinical response and symptom control. 1, 2

Dosing Guidelines and Titration

  • Initial dose: 500 mg orally twice daily 1
  • Maximum dose: 1000 mg orally twice daily 1, 2
  • Titration: Increase dose based on clinical symptoms and patient response 1
  • Formulation: Extended-release tablets only 1

Special Dosing Considerations

Medication Interactions

  • With moderate CYP3A inhibitors (e.g., diltiazem, verapamil, erythromycin): Limit ranolazine to 500 mg twice daily 1
  • With P-gp inhibitors (e.g., cyclosporine): Titrate ranolazine based on clinical response 1

Contraindications

  • Strong CYP3A inhibitors (e.g., ketoconazole, clarithromycin, nelfinavir) 1
  • CYP3A inducers (e.g., rifampin, phenobarbital, St. John's wort) 1
  • Liver cirrhosis 1

Clinical Efficacy and Position in Therapy

Ranolazine is indicated as:

  • Monotherapy for chronic angina 1
  • Add-on therapy when symptoms are inadequately controlled with beta-blockers and/or calcium channel blockers 2

The European Society of Cardiology recommends ranolazine as add-on therapy for patients with inadequate control of angina symptoms while on treatment with first-line agents 2.

Monitoring Requirements

  • Baseline assessment: ECG to evaluate QTc interval, renal function, hepatic function 2
  • Follow-up monitoring:
    • ECG after dose adjustments (due to QT prolongation risk) 2
    • Periodic renal function tests in at-risk patients 2
    • Symptom assessment for side effect management 2

Common Side Effects

  • Dizziness, headache, constipation, nausea 1
  • QTc interval prolongation (dose-related) 1, 2

Clinical Pearls

  • Ranolazine provides antianginal effects without reducing heart rate or blood pressure 3
  • Long-term studies show that ranolazine is generally well-tolerated in high-risk coronary heart disease patients 4
  • Ranolazine has been shown to reduce angina attacks by approximately one per week compared to placebo 5
  • Advanced age (≥64 years) may predict higher withdrawal rates due to adverse events 4

By following these dosing recommendations and monitoring guidelines, ranolazine can be effectively and safely used to manage chronic angina symptoms in appropriate patients.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.